Experimental Sjögren's Syndrome Model

Creative Bioarray possesses extensive experience in Sjögren's Syndrome research. Our dedicated team will collaborate closely with you, guiding you through every step of the process, from the selection of appropriate models and the design of study plans to the final data analysis and reporting. We have successfully established a stable Experimental Sjögren's Syndrome Model, which is instrumental in evaluating the efficacy of your drug candidates. Our commitment is to provide you with comprehensive support and reliable services to facilitate your research and development endeavors in the field of Sjögren's Syndrome.

Sjögren's Syndrome (SS) is a systemic autoimmune disease characterized primarily by the infiltration of lymphocytes into exocrine glands. This condition predominantly manifests as symptoms of dry mouth and dry eyes. The principal mechanism behind the development of SS is believed to involve the destruction of the exocrine gland epithelium, mediated by an abnormal response of immunocytes to autoantigens. Currently, there are no ideal drugs specifically designed for the treatment of SS. Treatment strategies primarily focus on symptomatic relief and systemic therapy, aimed at alleviating symptoms and slowing the progression of the disease. However, systemic therapies, including the use of glucocorticoids or immunosuppressive treatments, can lead to adverse effects such as gastrointestinal ulcers, immunosuppression, and even the development of tumors. Consequently, the quest for safe and effective therapeutic options for SS remains a critical research focus.

Our Experiment Sjögren's Syndrome Model

Animal Species

  • Mouse

Modeling Method

  • Submandibular gland (SG) proteins are prepared by homogenizing the bilateral submandibular glands of C57BL/6 mice. The SG protein is then used for immunization on days 0, 7, and 14 to induce an experimental Sjögren's syndrome model.

Method for establishing an Experimental Sjögren's Syndrome ModelFig. 1 Modeling method of Experiment Sjögren's Syndrome Model

Endpoints

  • Body weight
  • Salivary flow rate
  • Salivary gland index
  • Histology analysis: H&E staining
  • Cytokine analysis
  • Other customized endpoints: according to your specific needs

Example Data

Effects of CP-25 on saliva flow, salivary gland indexes, and histological assessment in SS mice, showing increased saliva flow and reduced lymphocytic infiltration with treatment.Fig. 2 The effects of CP-25 on saliva flow, the salivary gland indexes, and histological assessment in SS mice. (A) CP-25 (35, 70 mg/kg) increased saliva flow in SS mice after a 2-week treatment. (B) CP-25 reduced the salivary gland indexes in SS mice. (C, D) CP-25 attenuated lymphocytic infiltration in the salivary gland and significantly improved histological scores in SS mice. (Wu et al.2021)

Quotation and Ordering

Creative Bioarray boasts a team of scientists with profound therapeutic expertise and extensive experience in the development and validation of models. We are committed to offering our clients the most dependable services at the most competitive prices. If you are interested in our services, please feel free to contact us at any time or submit an inquiry to us directly.

Reference

  1. Wu, H., et al. CP-25 alleviates antigen-induced experimental Sjögren's syndrome in mice by inhibiting JAK1-STAT1/2-CXCL13 signaling and interfering with B-cell migration. Laboratory Investigation, 2021, 101(8): 1084-1097.

For research use only. Not for any other purpose.